Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

/by

Authors: Javier Fernández‐Ruiz, Onintza Sagredo, M. Ruth Pazos, Concepción García, Roger Pertwee, et al
British Journal of Clinical Pharmacology, February 2013
—
Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous disorders exerted through molecular mechanisms that are yet to be completely identified. CBD acts in some experimental models as an anti-inflammatory, anticonvulsant, anti-oxidant, anti-emetic, an…

Read more

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease.

/by

Authors: Cristina Blázquez, Anna Chiarlone, Onintza Sagredo, Tania Aguado, M. Ruth Pazos, et al
Brain, January 2011
—
Endocannabinoids act as neuromodulatory and neuroprotective cues by engaging type 1 cannabinoid receptors. These receptors are highly abundant in the basal ganglia and play a pivotal role in the control of motor behaviour. An early downregulation of type 1 cannabinoid receptor…

Read more